Company Description

A pre-clinical stage biotech that not only develops modifier gene targets that make for more effective cell therapies but also discovers new receptors, called non-MHC restricted T cell receptors, that can safely (in contrast to CARs which are used by most of companies, e.g. Kite/Gilead, Juno/BMS, Novartis) and broadly (in contrast to some companies using MHC-resticted TCRs, e.g. Adaptimmune, Immunocore) target T cells to different cancers but not healthy essential tissue. OverT Bio operates as a biotech company that provide cell therapy for cancers.